NACDS conference exhibitors donate 6.5 tons of consumer goods through Conventions C.A.R.E.
ALEXANDRIA, Va. — As part of this year’s National Association of Chain Drug Stores Marketplace Conference in Boston, which came to a close Tuesday, NACDS conference exhibitors and Conventions C.A.R.E. dispersed 6.5 tons of consumer goods to various charitable organizations throughout the Greater Boston community.
NACDS worked with the Massachusetts Convention Center Authority’s Conventions C.A.R.E. program, which was established by the MCCA to benefit convention and trade show exhibitors, the convention centers and local nonprofits. Exhibitors are saved the time and expense of shipping unneeded goods after a show ends, while local nonprofits benefit from useful donations, such as boxes of toiletries or office supplies. The MCCA and its partners in turn help divert these items from local landfills. Marketplace exhibitors donated such products as cosmetics, health and hygiene products, food and beverages, household supplies and other consumer products available in chain pharmacies.
"During these challenging economic times, we are deeply grateful to NACDS’ associate member companies for their product contributions to help those in need in the Boston community," NACDS president and CEO Steve Anderson said. "NACDS is grateful to have a partner in the Conventions C.A.R.E. program to distribute these goods to local nonprofit groups."
Valeant buys rights for Elidel, Xerese
MISSISSAUGA, Ontario — Canadian drug maker Valeant Pharmaceuticals International will acquire rights to topical drugs for eczema and cold sores from Swedish drug maker Meda.
Valeant said it would buy rights for the eczema drug Elidel (pimecrolimus) and the cold sore drug Xerese (acyclovir and hydrocortisone) for the United States, Canada and Mexico. Valeant said, however, that Xerese has not yet received regulatory approval in Canada.
Valeant will pay Meda $76 million upfront and over the next 18 months will pay a series of potential milestone payments and royalties of about $130 million.
UCB, Harvard enter research alliance focused on central nervous system, immunology
BOSTON and BRUSSELS — Drug maker UCB and Harvard University have entered a research alliance that is designed to advance ongoing Harvard research projects along the drug development pathway.
UCB said it will bring its expertise in antibody generation and medicinal chemistry into the alliance and will provide up to $6 million over two years to fund specific innovative research projects led by Harvard scientists. The collaboration focuses on the central nervous system and immunology, UCB said.
The first research project funded under the Harvard-UCB alliance is a collaboration with Gokhan Hotamisligil, professor and chair of the department of genetics and complex diseases at the Harvard School of Public Health.
"Harvard’s world-class academic research is an excellent fit with UCB’s world-class antibody research and central nervous system pharmacology," said Ismail Kola, president of UCB new medicines. "Both parties will learn from each other through the collaboration and a two-way exchange of ideas. Harvard will benefit from UCB’s strengths and industry experience in drug discovery and development, while Harvard’s exceptional research will complement UCB’s internal expertise."